2022
DOI: 10.1016/j.ctro.2022.02.008
|View full text |Cite
|
Sign up to set email alerts
|

The value of plasma hypoxia markers for predicting imaging-based hypoxia in patients with head-and-neck cancers undergoing definitive chemoradiation

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

0
3
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
2
1

Relationship

1
2

Authors

Journals

citations
Cited by 3 publications
(3 citation statements)
references
References 75 publications
0
3
0
Order By: Relevance
“…Osteopontin is involved in several pathways related to proliferation, angiogenesis and immunosuppression in cancers including HNSCC [ 56 ]. Furthermore, both intratumoral and plasma osteopontin have been linked to tumor hypoxia, and secretion of osteopontin is increased in senescence-associated T cells, therefore considered as immunosenescence marker [ 44 , 45 , 47 , 51 , 57 ]. To the best of our knowledge, this is the first report about an association between tissue osteopontin levels and patient age among elderly HNSCC patients.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…Osteopontin is involved in several pathways related to proliferation, angiogenesis and immunosuppression in cancers including HNSCC [ 56 ]. Furthermore, both intratumoral and plasma osteopontin have been linked to tumor hypoxia, and secretion of osteopontin is increased in senescence-associated T cells, therefore considered as immunosenescence marker [ 44 , 45 , 47 , 51 , 57 ]. To the best of our knowledge, this is the first report about an association between tissue osteopontin levels and patient age among elderly HNSCC patients.…”
Section: Discussionmentioning
confidence: 99%
“…TIM3, LAG3 and CD96 are other ICs that are intensively studied as potential targets in preclinical studies and clinical trials [39][40][41][42][43]. While plasma levels of osteopontin, a bone sialoprotein, have shown to exhibit predictive value regarding tumor hypoxia and the potential benefit of the hypoxia modifier nimorazole [44,45], osteopontin was also found to be abundantly secreted by immunosenescent T cells [46,47].…”
Section: Introductionmentioning
confidence: 99%
“…The nal study [32] in Table 2 investigated the association between [ 18 F]FMISO PET imaging and plasma hypoxia markers (osteopontin, vascular endothelial growth factor (VEGF), galectin-3 and circulating tumour growth factor (CTGF)). The most promising result was obtained with serum osteopontin, a protein whose plasma concentration has been shown to increase in conditions of tumour hypoxia [32]. There was a moderate correlation between osteopontin levels and the baseline hypoxic volume (r=0.579), and residual hypoxia on [ 18 F]FMISO PET imaging (p<0.05) during treatment.…”
Section: Resultsmentioning
confidence: 99%